Tumor necrosis factor-alpha (TNF-α) inhibitors, such as infliximab (IFX), have been used to treat UC; however, TNF-α inhibitors can induce or exacerbate psoriasis.[2] Ixekizumab is a biologic drug approved for the treatment of psoriasis and psoriatic arthritis. This evidence concerns the gene TNF and psoriatic arthritis.